Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Tomoko Aoki

26PUBLICATIONS
65CO-AUTHORS
HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Biomedical imagingInnate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

Sort by Publication Date:
|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|Apr 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

|Apr 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka

|Mar 21, 2026
Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRI.

Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima

|Feb 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka

|Jan 29, 2026
Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab.

Kazuhiro Nouso, Akiko Wakuta, Shohei Shiota

Pageof 5

Frequent Collaborators

24 joint publications

Masatoshi Kudo

16 joint publications

Toru Ishikawa

16 joint publications

Kazuhito Kawata

16 joint publications

Takeshi Hatanaka

16 joint publications

Atsushi Naganuma

15 joint publications

Kazuto Tajiri

15 joint publications

Hidenori Toyoda

15 joint publications

Toshifumi Tada

15 joint publications

Hidekatsu Kuroda

15 joint publications

Takashi Kumada

Frequent Collaborators

24 joint publications

Masatoshi Kudo

16 joint publications

Toru Ishikawa

16 joint publications

Kazuhito Kawata

16 joint publications

Takeshi Hatanaka